Thanks @comora for your sentiments. It's difficult at the best...

Agreed @Shaunbra once the tide turns I think it will turn hard. Once again as always it's having the patience and funds to stay the course. For those in that position (as you suggested) I note one single product, be it Azer Cel, Vaxinia, Oncarlytics or even PD1 Vaxx, have huge potential given both their preclinical and ongoing trial data.

Thanks for your kind words @lukeben And agreed, the progress in the clinical arena is really outstanding.

Thanks for your response @kingkev I guess as holders we all seek to hold strong faith in management and their best endeavours to champion our cause. But at times we are all guilty of being too accepting and therein complicit in over reaching at the corporate level.

Thanks @hargeo I guess we must find resolve in the understanding that irrespective of decisions at board level pertaining to salaries Imugene is supported by extraordinary science and exceptional minds, including but not limited to YF, SP, UW and PK. And whilst PH is indeed responsible for much of the excess, the failure to divine commercial outcomes and indeed ongoing dilution, he did create the science upon which we rest our laurels.

That said this years AGM surely needs to hold him accountable for the ever present malais surrounding the stock. He and his counterparts need to focus heavily upon commercial outcomes, as opposed to perceived potential and unfulfilled promises.

Thanks @comora for your sentiments. It's difficult at the best of times to stay rusted on. Many of us are so confident in the science and so enamoured by Imugene's prodigious talent, yet forever frustrated at the lack of results at the commercial level. I'm unclear as to how we reposition the deck chairs toward monetary gains, given the company's past performance and existing management structure. Suffice to say if you are in a position to continue holding post the inevitable capital raises akin to the stock, surely the number of shots on goal should pay dividends for you and those comfortable with risk. Imugene still has the potential to be a market leader, with recent results doing nothing to diminish this enviable position.

BTW I haven't just stopped by. I'm still an ever present supporter of this company's amazing science. I'm merely awaiting more news on Vaxinia and Oncarlytics before being in a position to add to the debate. Though whether its Imugene's B cell platform, (incorporating PD1 Vaxx and Her Vaxx), or their various oncolytic viral drugs, I'm confident prospective success in their Phase 2 trials, if forthcoming, is set to reward those holding firm with IMU.

In the interim the ebs and flows associated with ongoing capital requirements are no doubt set to test us even further.

DYOR Opinions only